Uploaded December 2024 | Updated September 2026, 1 week ago

---

Synopsis:

Exciting new advances are underway for the treatment of patients with blood disorders such as sickle cell anemia and thalassemia. Understanding the basic science behind the mechanisms regulating fetal hemoglobin (HbF) is critical to exploring these novel therapeutics. Innovative research conducted at the Orkin lab has led to advancements in techniques for re-expressing HbF in adult red blood cells. In our annual Rudi Schmid Lecture, Stuart Orkin, MD, a Howard Hughes Medical Institute Investigator, will discuss the challenges and recent progress in using HbF reactivation as a therapeutic approach for hematologic diseases.

Speaker:
Stuart Orkin, MD

Program
Lekshmi Santhosh: Introduction
2:41-52:22 — Stuart Orkin, MD
52:22-54:44 — Q&A

See previous Medical Grand Rounds:
December 5: Preparing Clinicians for Diagnostic Artificial Intelligence: Tools, Teammates, and Teaching
• youtu.be/JiWULSSLwnI
November 19: Multidisciplinary Approach to the Diagnosis and Treatment of Pulmonary Hypertension
• youtu.be/hbTE9yQ5G1Y
November 12: Advances in Rheumatoid Arthritis 2024: From Bench to Bedside
• youtu.be/mdztWUW1lFw
November 5: Community-Engaged Climate Change Solutions
• youtu.be/YhN4K7eA7Kk